RxDoctor Payments Data

Trevor Williams, PA

Physician Assistant · Bakersfield, CANPI 1477805554

Payments from drug & device makers

$773in general payments, 2019–2025

Across 44 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$235
  • AbbVie$138
  • Bayer$73
  • Otsuka America Pharmaceutical, Inc.$45
  • Sanofi-aventis U.S. LLC$42
  • Boehringer Ingelheim$41
  • plus $200 from 9 others

What the payments were for

  • Food & beverage$773100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$773 in reported general payments places this provider in the 65th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$246,183
Medicare patients
559
Services billed
5,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol239$206,350
OzempicSemaglutide134$159,942
JardianceEmpagliflozin112$122,791
EliquisApixaban111$111,887
MounjaroTirzepatide42$63,379
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog48$51,613
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$37,028
Tresiba Flextouch U-100Insulin Degludec35$26,657
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$26,319
JanuviaSitagliptin Phosphate35$26,257
Bydureon BciseExenatide Microspheres21$23,802
Tresiba Flextouch U-200Insulin Degludec23$20,012
TradjentaLinagliptin23$14,494
XareltoRivaroxaban16$12,253
DapagliflozinDapagliflozin Propanediol20$11,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$235$206,350239 claims
Novo NordiskOzempic$14$159,942134 claims
Boehringer IngelheimJardiance, Tradjenta$41$137,285135 claims
Lilly USA, LLCMounjaro$26$63,37942 claims
GSKTrelegy Ellipta, Breo Ellipta$31$45,00565 claims
MerckJanuvia$29$26,25735 claims
AbbVieSynthroid$138$3,30049 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →